I agree that this site is using cookies. You can find further informations here.
X
Leppä, S.
150  results:
Search for persons X
?
1

GLOFITAMAB MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY..:

Dickinson, M. ; Carlo‐Stella, C. ; Morschhauser, F....
Hematological Oncology.  41 (2023)  S2 - p. 144-146 , 2023
Link: https://doi.org/10.1002/..
 
?
2

BIOMARKER‐DRIVEN TREATMENT STRATEGY IN HIGH‐RISK LARGE B‐CE..:

Leppa, S. ; Meriranta, L. ; Arffman, M....
Hematological Oncology.  41 (2023)  S2 - p. 51-52 , 2023
Link: https://doi.org/10.1002/..
 
?
3

Final safety and efficacy results of copanlisib monotherapy..:

Dreyling, M. ; Santoro, A. ; Mollica, L....
Hematological Oncology.  41 (2023)  S2 - p. 560-562 , 2023
Link: https://doi.org/10.1002/..
 
?
4

TOBACCO SMOKING IMPAIRS SURVIVAL IN LYMPHOMA PATIENTS IN TW..:

Reunamo, T. ; Mikkola, T. ; Laitinen, T....
Hematological Oncology.  41 (2023)  S2 - p. 612-613 , 2023
Link: https://doi.org/10.1002/..
 
?
5

EPCORITAMAB WITH RITUXIMAB + LENALIDOMIDE (R2) PROVIDES DUR..:

Belada, D. ; Falchi, L. ; Leppä, S....
Hematological Oncology.  41 (2023)  S2 - p. 125-127 , 2023
Link: https://doi.org/10.1002/..
 
?
6

Enhanced ctDNA Profiling Reveals Molecular Determinants of ..:

Meriranta, L. ; Kolstad, A. ; Hutchings, M....
Hematological Oncology.  41 (2023)  S2 - p. 477-478 , 2023
Link: https://doi.org/10.1002/..
 
?
7

LONG‐TERM FOLLOW‐UP AND GENE EXPRESSION PROFILES ASSOCIATED..:

Relander, T. ; Leivonen, S. ; Larsen, T. S....
Hematological Oncology.  41 (2023)  S2 - p. 309-310 , 2023
Link: https://doi.org/10.1002/..
 
?
8

P1135: SUBCUTANEOUS EPCORITAMAB IN COMBINATION WITH RITXUIM..:

Belada, D. ; Leppä, S. ; Wahlin, B. E....
HemaSphere.  6 (2022)  - p. 1025-1026 , 2022
Link: https://doi.org/10.1097/..
 
?
9

CHARACTERIZATION OF CANCER ASSOCIATED FIBROBLASTS IN CLASSI..:

Karihtala, K. ; Leivonen, S.‐K. ; Karjalainen‐Lindsberg, M.‐L....
Hematological Oncology.  39 (2021)  S2 - p. , 2021
Link: https://doi.org/10.1002/..
 
?
10

BIOMARKER‐DRIVEN TREATMENT STRATEGY IN HIGH RISK DIFFUSE LA..:

Leppä, S ; Jørgensen, J ; Karjalainen‐Lindsberg, M‐L...
Hematological Oncology.  39 (2021)  S2 - p. , 2021
Link: https://doi.org/10.1002/..
 
?
11

FINAL ANALYSIS OF A NORDIC LYMPHOMA GROUP PHASE IB/IIA TRIA..:

d'Amore, F ; Leppä, S ; Relander, T...
Hematological Oncology.  39 (2021)  S2 - p. , 2021
Link: https://doi.org/10.1002/..
 
?
12

HIGH RISK AGGRESSIVE B‐CELL LYMPHOMA ON THE LIQUID BIOPSY:

Meriranta, L ; Alkodsi, A ; Pasanen, A...
Hematological Oncology.  39 (2021)  S2 - p. , 2021
Link: https://doi.org/10.1002/..
 
?
13

SAFETY ANALYSIS OF PATIENTS WITH A MEDICAL HISTORY OF RESPI..:

Zinzani, P.L. ; Santoro, A. ; Leppä, S....
Hematological Oncology.  37 (2019)  S2 - p. 389-390 , 2019
Link: https://doi.org/10.1002/..
 
?
14

EFFICACY AND SAFETY IN HIGH‐RISK RELAPSED OR REFRACTORY IND..:

Dreyling, M. ; Santoro, A. ; Leppä, S....
Hematological Oncology.  37 (2019)  S2 - p. 387-389 , 2019
Link: https://doi.org/10.1002/..
 
?
15

PROGNOSTIC VALUE OF BASELINE FDG PET PARAMETERS IN HIGH RIS..:

Fiskvik, I. ; Stokke, C. ; Mikalsen, L.G....
Hematological Oncology.  37 (2019)  S2 - p. 411-411 , 2019
Link: https://doi.org/10.1002/..
 
1-15